Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Kyowa Hakko Released Mid-Term Business Plan For 2008-2010

This article was originally published in PharmAsia News

Executive Summary

Kyowa Hakko released its mid-term business plan for fiscal years 2008-2010. Based on the integration of Kyowa Hakko and Kirin Pharma, the plan estimates net sales to reach ¥513 billion, with ¥73 billion in income before goodwill amortization and a 30+ percent dividend payout ratio by 2010. To maintain top class biopharma production, Kyowa Hakko plans to build a new antibody drug production facility inside its bio technology institute in Takasaki, Gunma Prefecture. The company also plans to build a new research facility inside the Tokyo Research Park. Total capital investment will be ¥83 billion. On the same day, Kyowa Hakko reported results for the past fiscal year ending March 31, with both sales (¥392 billion) and net income (¥23.4 billion) the highest in the company's history. (Click here for more - Japanese language

You may also be interested in...

Filgotinib On Uncertain Path As Gilead Regains Speed From Pandemic Hit

Third quarter earnings show Gilead’s Immunomedics buy paid off, but filgotinib’s path may narrow. The HIV and HCV franchises picked up from their COVID-19 lull.

Google Teams Up With Mayo Clinic To Explore AI To Improve Radiotherapy Planning

Mayo Clinic announces AI-based partnerships with Google and voice-analysis company Vocalis Health this week.

FDA’s Final MOU On Interstate Compounding Now Awaits Signatures From States

US pharmacy group says that 10 to 12 states have indicated through an informal survey that they do not have the manpower or funding to implement the US FDA’s final MOU on inordinate compounding. They say what is at stake in these states is patient access to compounded medicines.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts